Clinical Trial Update: A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder [Phase 1]

View source ↗

Summary

Phase 1 multiple ascending dose study evaluating safety, tolerability, and pharmacokinetics of DSP-1053 and its metabolites in healthy subjects and in individua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• DSP-1053

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Healthy | Phase 1 | Status: TERMINATED